Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.97B 3.76B 3.4B 6.36B 437B 6.42B 44.79B 17.28B 221B 17.09B 16.71B 711B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.1B 3.88B 3.51B 6.57B 451B 6.63B 46.25B 17.85B 229B 17.65B 17.26B 734B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+0.84%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.68
Extreme 7.68
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
27/4/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/4/26 Issuer sale

Director

395,940 0.1261%
27/4/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+87.45%+10.70% 4.55B
+0.22%-3.17%-1.61%+8.24% 45.81B
-4.36%-5.50%+324.07%+516.88% 43.91B
-0.32%+3.71%+44.55%+26.98% 44.39B
+0.46%-0.97%+4.76%+73.76% 39.4B
-0.17%-3.22%+9.45%+38.69% 31.26B
+3.30%-8.29% - - 15.75B
-0.65%+4.32%+24.18%+120.17% 17.32B
+1.66%+4.92%+18.42%+34.93% 14.73B
+0.19%-2.62%+79.59%+31.52% 13.03B
Average +0.46%-0.95%+65.65%+95.76% 27.01B
Weighted average by Cap. +0.24%-1.08%+73.67%+123.60%

Financials

2024 2025
Net sales 528M 461M 436M 395M 739M 50.68B 745M 5.2B 2.01B 25.71B 1.98B 1.94B 82.53B 634M 553M 524M 474M 887M 60.85B 895M 6.24B 2.41B 30.86B 2.38B 2.33B 99.08B
Net income -56.11M -48.93M -46.33M -41.93M -78.48M -5.38B -79.17M -552M -213M -2.73B -211M -206M -8.76B -27.11M -23.64M -22.39M -20.26M -37.92M -2.6B -38.25M -267M -103M -1.32B -102M -99.57M -4.24B
Net Debt 194M 169M 160M 145M 271M 18.58B 273M 1.91B 736M 9.43B 728M 711M 30.26B 149M 130M 123M 111M 208M 14.28B 210M 1.46B 565M 7.24B 559M 547M 23.25B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!